Stoke Therapeutics, Inc. STOK Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Stoke Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The official record: Stoke Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Stoke Therapeutics, Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Stoke Therapeutics, Inc.'s cash & equivalents?
- Stoke Therapeutics, Inc. (STOK) reported cash & equivalents of $155.66M in Q1 2026.
- How has Stoke Therapeutics, Inc.'s cash & equivalents changed year-over-year?
- Stoke Therapeutics, Inc.'s cash & equivalents decreased by 43.4% year-over-year, from $274.82M to $155.66M.
- What is the long-term trend for Stoke Therapeutics, Inc.'s cash & equivalents?
- Over 5 years (2020 to 2025), Stoke Therapeutics, Inc.'s cash & equivalents has grown at a -21.8% compound annual growth rate (CAGR), from $287.31M to $84.22M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.